We are one of the few research centers in the world that creates multi-targeted immunotherapy for the new generation.
Only in our center there is a know-how that allows you to get the most efficacy in cancer immunotherapy.
Innovative techniques have no analogues in the world.
Components of success:
1. Action on 9 target proteins
2. Personal molecules for each patient
3. SMART molecules that have the properties of mixed agonists - antagonists. That is, they selectively inhibit hyperactive proteins and stimulate passive "silent" proteins.
All this allows you to get the maximum effect from personal therapy.
4. Safety for the patient. The data in the study of acute toxicity "Mercureid" lead to the conclusion - with intragastric introduction, the study drug does not produce toxic effects on the body. The preparation according to the classification of substances for toxicity, is a class IV toxicity (lowest possible low toxic substance), 501 <LD50 <5000 mg / kg.
We are here with a very great news regarding your article submitted towards AS Cancer Biology entitled “Results Of Multitarget Therapy Anti-Pd-1 / Pd-L1 / Cd19 / Cd25 / Cd38 With Application Of Msc-428 Molecules In Patients With Different Oncopathology”, the Editorial Panel of AS Cancer Biology has elected “Best Article of the Issue” from Volume 2 &Issue 10. We are glad to notify you that, your article has been elected as the Best One among all other articles in the particular issue. We heartily congratulate you on this occasion.
Please have a glance at the below link.
See video for more details: